Talk:Tisagenlecleucel

Bach JAMA 2007
Here's a proper WP:MEDRS to add to the primary sources and press releases. Not only is this a good discussion of the price, it also clearly explains the technology.

https://jamanetwork.com/journals/jama/article-abstract/2654900 Viewpoint November 21, 2017 FDA Approval of TisagenlecleucelPromise and Complexities of a $475 000 Cancer Drug Peter B. Bach, MD1; Sergio A. Giralt, MD1; Leonard B. Saltz, MD1 JAMA. 2017;318(19):1861-1862. doi:10.1001/jama.2017.15218 --Nbauman (talk) 21:27, 25 November 2017 (UTC)

History Section Update
Suggest replacement of current final sentence which lacks citation with more accurate updated information. Current: "The drug has been licensed to treat adults with diffuse large B-cell lymphoma (DLBCL), but as of September 2018 it had not been decided whether the NHS would use it.[citation needed]" Replacement: "In March 2019 NICE issued guidance approving Kymriah for treatment of relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies. DonInUtah (talk) 03:09, 28 July 2021 (UTC)

I put this live as it replaces an uncited/outdated sentence with more accurate information from the UK government, and there was no commentary on the change. DonInUtah (talk) 19:10, 3 August 2021 (UTC)